200 related articles for article (PubMed ID: 27531416)
21. Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees.
Morin TJ; Broering TJ; Leav BA; Blair BM; Rowley KJ; Boucher EN; Wang Y; Cheslock PS; Knauber M; Olsen DB; Ludmerer SW; Szabo G; Finberg RW; Purcell RH; Lanford RE; Ambrosino DM; Molrine DC; Babcock GJ
PLoS Pathog; 2012; 8(8):e1002895. PubMed ID: 22952447
[TBL] [Abstract][Full Text] [Related]
22. Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization.
Vercauteren K; Mesalam AA; Leroux-Roels G; Meuleman P
World J Gastroenterol; 2014 Nov; 20(43):15975-91. PubMed ID: 25473151
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis C virus reinfection after liver transplantation: is there a role for direct antiviral agents?
Dall'Agata M; Gramenzi A; Biselli M; Bernardi M
World J Gastroenterol; 2014 Jul; 20(28):9253-60. PubMed ID: 25071318
[TBL] [Abstract][Full Text] [Related]
24. A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies.
Wasilewski LN; El-Diwany R; Munshaw S; Snider AE; Brady JK; Osburn WO; Ray SC; Bailey JR
J Virol; 2016 Jan; 90(7):3773-82. PubMed ID: 26819308
[TBL] [Abstract][Full Text] [Related]
25. Low cross-neutralization of hepatitis C correlates with liver disease in immunocompromized patients.
Maurin G; Halgand B; Bruscella P; Fresquet J; Duclos-Vallée JC; Roque-Afonso AM; Cosset FL; Samuel D; Lavillette D; Féray C
AIDS; 2015 Jun; 29(9):1025-33. PubMed ID: 26125137
[TBL] [Abstract][Full Text] [Related]
26. Optimization of the pseudoparticle system for standardized assessments of neutralizing antibodies against hepatitis C virus.
Chumbe A; Urbanowicz RA; Sliepen K; Koekkoek SM; Molenkamp R; Tarr AW; Ball JK; Schinkel J; van Gils MJ
J Gen Virol; 2022 Nov; 103(11):. PubMed ID: 36399377
[TBL] [Abstract][Full Text] [Related]
27. A Novel Approach To Display Structural Proteins of Hepatitis C Virus Quasispecies in Patients Reveals a Key Role of E2 HVR1 in Viral Evolution.
Tong Y; Li Q; Li R; Xu Y; Pan Y; Niu J; Zhong J
J Virol; 2020 Aug; 94(17):. PubMed ID: 32554700
[TBL] [Abstract][Full Text] [Related]
28. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
[TBL] [Abstract][Full Text] [Related]
29. The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition.
Crespo G; Trota N; Londoño MC; Mauro E; Baliellas C; Castells L; Castellote J; Tort J; Forns X; Navasa M
J Hepatol; 2018 Jul; 69(1):11-17. PubMed ID: 29481821
[TBL] [Abstract][Full Text] [Related]
30. An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development.
Salas JH; Urbanowicz RA; Guest JD; Frumento N; Figueroa A; Clark KE; Keck Z; Cowton VM; Cole SJ; Patel AH; Fuerst TR; Drummer HE; Major M; Tarr AW; Ball JK; Law M; Pierce BG; Foung SKH; Bailey JR
Gastroenterology; 2022 Feb; 162(2):562-574. PubMed ID: 34655573
[TBL] [Abstract][Full Text] [Related]
31. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.
Keck ZY; Li SH; Xia J; von Hahn T; Balfe P; McKeating JA; Witteveldt J; Patel AH; Alter H; Rice CM; Foung SK
J Virol; 2009 Jun; 83(12):6149-60. PubMed ID: 19321602
[TBL] [Abstract][Full Text] [Related]
32. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.
Wong JA; Bhat R; Hockman D; Logan M; Chen C; Levin A; Frey SE; Belshe RB; Tyrrell DL; Law JL; Houghton M
J Virol; 2014 Dec; 88(24):14278-88. PubMed ID: 25275133
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype.
Tarr AW; Urbanowicz RA; Hamed MR; Albecka A; McClure CP; Brown RJ; Irving WL; Dubuisson J; Ball JK
J Virol; 2011 May; 85(9):4246-57. PubMed ID: 21325403
[TBL] [Abstract][Full Text] [Related]
34. Distinct Immune Imprints of Post-Liver Transplantation Hepatitis C Persist Despite Viral Clearance.
Aregay A; Engel B; Port K; Vondran FWR; Bremer B; Niehaus C; Khera T; Richter N; Jaeckel E; Cornberg M; Taubert R; Wedemeyer H
Liver Transpl; 2021 Jun; 27(6):887-899. PubMed ID: 33641215
[TBL] [Abstract][Full Text] [Related]
35. Improved liver transplant waitlist mortality and lower risk of disease progression among chronic hepatitis C patients awaiting liver transplantation after the introduction of direct-acting antiviral therapies in the United States.
Young K; Liu B; Bhuket T; Gish RG; Wong RJ
J Viral Hepat; 2019 Mar; 26(3):350-361. PubMed ID: 30412318
[TBL] [Abstract][Full Text] [Related]
36. Management of recurrent hepatitis C virus after liver transplantation.
Jiménez-Pérez M; González-Grande R; Rando-Muñoz FJ
World J Gastroenterol; 2014 Nov; 20(44):16409-17. PubMed ID: 25469009
[TBL] [Abstract][Full Text] [Related]
37. Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants.
Yokokawa H; Shinohara M; Teraoka Y; Imamura M; Nakamura N; Watanabe N; Date T; Aizaki H; Iwamura T; Narumi H; Chayama K; Wakita T
PLoS One; 2022; 17(9):e0274283. PubMed ID: 36137152
[TBL] [Abstract][Full Text] [Related]
38. A cinnamon-derived procyanidin type A compound inhibits hepatitis C virus cell entry.
Fauvelle C; Lambotin M; Heydmann L; Prakash E; Bhaskaran S; Vishwaraman M; Baumert TF; Moog C
Hepatol Int; 2017 Sep; 11(5):440-445. PubMed ID: 28698985
[TBL] [Abstract][Full Text] [Related]
39. Retrospective-prospective study of safety and efficacy of sofosbuvir-based direct-acting antivirals in HIV/HCV-coinfected participants with decompensated liver disease pre- or post-liver transplant.
Peters MG; Kottilil S; Terrault N; Amara D; Husson J; Huprikar S; Florman S; Sulkowski MS; Durand CM; Luetkemeyer AF; Rogers R; Grab J; Haydel B; Blumberg E; Dove L; Emond J; Olthoff K; Smith C; Fishbein T; Masur H; Stock PG
Am J Transplant; 2021 May; 21(5):1780-1788. PubMed ID: 33277801
[TBL] [Abstract][Full Text] [Related]
40. Study of Quasispecies Complexity and Liver Damage Progression after Liver Transplantation in Hepatitis C Virus Infected Patients.
Llorens-Revull M; Gregori J; Dopazo C; Rodriguez-Frías F; Garcia-Cehic D; Soria ME; Chen Q; Rando A; Perales C; Esteban JI; Quer J; Bilbao I
Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
